| 1. |
- Börjeson, Sussanne, 1962-, et al.
(författare)
-
Onkologisk omvårdnad
- 2008. - 1
-
Ingår i: Onkologi. - : Liber AB. ; , s. 232-242
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- Onkologisk omvårdnad har utvecklats i ett nära och unikt samarbete mellan kliniska specialister och erfarna lärare inom området. Boken är indelad i tre delar som var för sig behandlar olika specialområden inom onkologisk vård. Del I ägnas i sin helhet åt de olika kunskaper och färdigheter som sjuksköterskan bör besitta för att kunna tillgodose de behov patienter med cancer och deras närstående har i mötet med sjukdomen och behandlingen. Del II ger en introduktion i allmän onkologi med epidemiologi, genetik, klassifikation, diagnostik, behandlingsprinciper och behandlingsformer. Del III beskriver de viktigaste sjukdomsgrupperna, deras behandling samt speciella omvårdnadsproblem och åtgärder. Boken riktar sig i första hand till specialistutbildningen till onkologisjuksköterska och till sjuksköterskor som är verksamma på sjukhus eller andra vårdinstitutioner samt inom hemsjukvården. Vissa delar är även lämpliga för grundutbildningen.
|
|
| 2. |
- Enblom, Anna, et al.
(författare)
-
One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient
- 2009
-
Ingår i: Supportive Care in Cancer. - : Springer. - 0941-4355 .- 1433-7339. ; 17:1, s. 23-32
-
Tidskriftsartikel (refereegranskat)abstract
- Objective: To describe the prevalence of nausea and vomiting during radiotherapy and to compare quality of life, psychological and functional status in patients experiencing or not experiencing nausea.Materials and methods: A cross-sectional selection of 368 cancer patients treated with radiotherapy answered a questionnaire (=93% answering rate) regarding nausea, vomiting, actual use of and interest in antiemetic treatment, quality of life and psychological and functional status during the preceding week of radiotherapy. Mean age was 60 years and 66% were women.Main results: Nausea was experienced by 39% ( 145) and vomiting by 7% ( 28) of patients in general, by 63% in abdominal or pelvic fields and by 48% in head/neck/brain fields. Abdominal/pelvic field (Relative risk (RR) 2.0), age <= 40 years (RR 1.9) and previous nausea in other situations (RR 1.8) implied an increased risk for nausea. Antiemetics were used by 17% and 78% were interested in or wanted more information about acupuncture treatment against nausea. Of the 145 nauseous patients only 25% felt that antiemetics had helped them and 34% would have liked additional treatment, although the nausea intensity was mild in 72%. The nauseous patients reported lower well-being and quality of life, lower satisfaction with aspects of daily living and more frequent anxiety and depressed mood than the patients without nausea.Conclusions: Of all patients undergoing radiotherapy, 39% experienced nausea and one third of them would have liked more treatment against the nausea. This study stresses the importance to identify and adequately treat patients with increased risk for nausea related to radiotherapy.
|
|
| 3. |
- Grunberg, S, et al.
(författare)
-
Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-an update
- 2005
-
Ingår i: Supportive Care in Cancer. - : Springer Science and Business Media LLC. - 0941-4355 .- 1433-7339. ; 13:2, s. 80-84
-
Tidskriftsartikel (refereegranskat)abstract
- Development of effective antiemetic therapy depends upon an understanding of both the antiemetic agents and the emetogenic challenges these agents are designed to address. New potential antiemetic agents should be studied in an orderly manner, proceeding from phase I to phase II open-label trials and then to randomized double-blind phase III trials comparing new agents and regimens to best standard therapy. Use of placebos in place of antiemetic therapy against highly or moderately emetogenic chemotherapy is unacceptable. Nausea and vomiting should be evaluated separately and for both the acute and delayed periods. Defining the emetogenicity of new antineoplastic agents is a challenge, since such data are often not reliably recorded during early drug development. A four-level classification system is proposed for emetogenicity of intravenous antineoplastic agents. A separate four-level classification system for emetogenicity of oral antineoplastic agents, which are often given over an extended period of time, is also proposed.
|
|
| 4. |
- Hursti, T. J., et al.
(författare)
-
Effect of chemotherapy on circulating gastrointestinal hormone levels in ovarian cancer patients: relationship to nausea and vomiting
- 2005
-
Ingår i: Scand J Gastroenterol. - : Taylor & Francis. - 0036-5521 .- 1502-7708. ; 40:6, s. 654-61
-
Tidskriftsartikel (refereegranskat)abstract
- OBJECTIVE: The introduction of 5-HT3 receptor antagonists greatly reduced the problems associated with nausea and vomiting immediately after cancer chemotherapy. However, delayed nausea and vomiting is still a major problem and the underlying mechanism is obscure. MATERIAL AND METHODS: We studied the effect of cisplatin-containing combination chemotherapy in 14 ovarian cancer patients on the levels of gastrin and a panel of other hormones as well as glucose and prostaglandin F2a. Blood samples were obtained once daily in the morning before chemotherapy and for 4 days after chemotherapy. RESULTS: Concentrations of many hormones including gastrin were generally high. A pronounced increase in plasma insulin levels occurred on the day after chemotherapy accompanied by a modest increase in plasma glucose concentrations. Minor increases were observed for gastrin, oxytocin and prostaglandin F2a. In contrast, a transient decrease after chemotherapy was observed for motilin. Plasma cortisol decreased markedly after chemotherapy as expected since betamethasone was given as an antiemetic prophylaxis. Certain trends concerning the relationship between some hormones and nausea and vomiting were noted. A high plasma gastrin concentration before chemotherapy was related to delayed vomiting. Relative day-to-day variability of cholecystokinin tended to correlate positively with delayed nausea, whereas an inverse relationship was observed for gastrin variability. CONCLUSIONS: Changes in hormone plasma levels were found but only few could be distinguished as possible mediators of delayed nausea and vomiting.
|
|
| 5. |
- Kris, M, et al.
(författare)
-
Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy
- 2005
-
Ingår i: Supportive Care in Cancer. - : Springer Science and Business Media LLC. - 0941-4355 .- 1433-7339. ; 13:2, s. 85-96
-
Tidskriftsartikel (refereegranskat)abstract
- This paper uses an evidence-based approach whenever possible to formulate recommendations, emphasizing the results of controlled trials concerning the best use of antiemetic agents. We address issues of dose, schedule, and route of administration of five selective 5-HT3 antagonists. We conclude that for each of these five drugs, there is a plateau in therapeutic efficacy above which further dose escalation does not improve outcome. Furthermore, for all classes of antiemetic agents, a single dose is as effective as multiple doses or a continuous infusion. The oral route is as efficacious as the intravenous route of administration, even with chemotherapy of high emetic risk. Selective antagonists of the type 3 serotonin receptor (5-HT3) in combination with dexamethasone and aprepitant are the standard of care for the prevention of emesis following chemotherapy of high emetic risk.
|
|
| 6. |
- Molassiotis, Alex, et al.
(författare)
-
Nausea and vomiting
- 2006. - 1
-
Ingår i: Nursing patients with cancer. - : Elsevier Churchill Livingstone. - 9780443072888 - 0443072884 ; , s. 415-437
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- This title is directed primarily towards health care professionals outside of the United States. Nurses are in the vanguard of the international fight against cancer. National policies on reducing or eradicating cancer highlight the vital contribution nurses make in its prevention, identification, treatment and management. This book, which is based on the internationally acclaimed Core Curriculum for a Post-Registration Course in Cancer Nursing developed by the European Oncology Nursing Society (EONS), covers all the key areas nurses caring for patients in this demanding specialty will need to consider. Focusing on the needs of the patient, it provides the essential scientific, psychological and sociological information necessary for nurses to provide care that minimises the trauma of cancer, and maximises outcomes for
|
|
| 7. |
- Tishelman, Carol, et al.
(författare)
-
Using undergraduate nursing students as mediators in a knowledge transfer programme for care for patients with advanced cancer
- 2008
-
Ingår i: European Journal of Cancer Care. - : Hindawi Limited. - 0961-5423 .- 1365-2354. ; 17:3, s. 253-260
-
Tidskriftsartikel (refereegranskat)abstract
- Nursing today faces numerous challenges. Societal changes lead to reorganization of health care, changing workloads with sicker patients in hospital and home care, and limited economic resources. The increasing and changing nature of knowledge needed for expert care provision challenges nurses to continually update their competencies. These are issues demanding proactive and dynamic changes in the way nurses conceive their mandates and practice. The aim of the action-research project presented here was to foster improved quality of care for patients with advanced cancer through collaborative endeavours integrating cancer nursing clinical practice, research and education in a knowledge exchange programme. The programme was based on input about caregiving needs from multi-professional staff caring for patients with advanced cancer in a variety of healthcare settings. Undergraduate baccalaureate nursing students were then engaged in literature studies to help address these needs. Results of the studies were communicated back to the involved clinicians in a variety of ways. In this paper, we discuss what we have experienced as opportunities and obstacles in conducting the project, based on our reflections and external evaluations. This is linked to a broader discussion of ways of integrating cancer nursing research, education and practice.
|
|
| 8. |
- Tonato, M, et al.
(författare)
-
Emesis induced by low or minimal emetic risk chemotherapy
- 2005
-
Ingår i: Supportive Care in Cancer. - : Springer Science and Business Media LLC. - 0941-4355 .- 1433-7339. ; 13:2, s. 109-111
-
Tidskriftsartikel (refereegranskat)abstract
- For patients treated with low or minimally emetogenic chemotherapy there is little evidence from clinical trials supporting the choice of a given antiemetic therapy or of any treatment at all. The panel recognized the necessity of considering the introduction into clinical practice of new agents in these categories, particularly oral cytotoxic agents and targeted biological agents and also the possibility of over-treatment with antiemetics. There was consensus among panel members regarding the recommended treatment for patients receiving chemotherapy agents with low and minimal emetic risk. Patients without a history of nausea and vomiting for whom minimally emetic risk chemotherapy is prescribed should not routinely receive antiemetic prophylaxis. A single agent such as a low-dose corticosteroid is suggested for patients receiving agents of low emetic risk. If nausea and vomiting occurs during subsequent cycles of chemotherapy, prophylaxis with a single agent such as a substituted benzamide, a corticosteroid, or a phenothiazine should be administered. Only patients with persistent nausea and vomiting despite treatment with these recommended agents should receive a 5-HT3 receptor antagonist in the following cycles.
|
|
| 9. |
|
|
